Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Highlights
The gross profit has increased by 4.6% year-on-year
The revenue has grown by 4.5% YoY
Abbott Laboratories's net income has increased by 37% YoY but it has decreased by 2.9% QoQ
The EPS has grown by 36% YoY but it has contracted by 2.4% from the previous quarter
ABT's quick ratio is down by 12% year-on-year and by 6% since the previous quarter
ABT's equity is down by 2.8% since the previous quarter and by 2.3% year-on-year
Key stats
What are the main financial stats of ABT
Market
Shares outstanding
1.77B
Market cap
$176.87B
Enterprise value
$191.76B
Valuations
Price to earnings (P/E)
49.5
Price to book (P/B)
5.8
Price to sales (P/S)
5.51
EV/EBIT
40.49
EV/EBITDA
24.51
EV/Sales
5.97
Earnings
Revenue
$32.1B
EBIT
$4.74B
EBITDA
$7.83B
Free cash flow
$4.48B
Per share
EPS
$2.02
Free cash flow per share
$2.53
Book value per share
$17.25
Revenue per share
$18.14
TBVPS
$15.59
Balance sheet
Total assets
$66.78B
Total liabilities
$36.35B
Debt
$18.27B
Equity
$30.43B
Working capital
$4.69B
Liquidity
Debt to equity
0.6
Current ratio
1.43
Quick ratio
0.83
Net debt/EBITDA
1.9
Margins
EBITDA margin
24.4%
Gross margin
58.4%
Net margin
11.2%
Operating margin
14.2%
Efficiency
Return on assets
5.3%
Return on equity
11.4%
Return on invested capital
14.7%
Return on capital employed
8.5%
Return on sales
14.8%
Dividend
Dividend yield
1.4%
DPS
$1.4
Payout ratio
69.3%
ABT stock price
How has the Abbott Laboratories stock price performed over time
Financial performance
How have Abbott Laboratories's revenue and profit performed over time
Revenue
$32.1B
Gross profit
$18.74B
Operating income
$4.55B
Net income
$3.58B
Gross margin
58.4%
Net margin
11.2%
Abbott Laboratories's net income has increased by 37% YoY but it has decreased by 2.9% QoQ
Abbott Laboratories's net margin has increased by 32% YoY but it has decreased by 3.4% QoQ
The operating income has grown by 20% YoY
Abbott Laboratories's operating margin has increased by 15% YoY
Valuation
What is Abbott Laboratories stock price valuation
P/E
49.5
P/B
5.8
P/S
5.51
EV/EBIT
40.49
EV/EBITDA
24.51
EV/Sales
5.97
The EPS has grown by 36% YoY but it has contracted by 2.4% from the previous quarter
ABT's P/E is 29% below its 5-year quarterly average of 69.2 but 12% above its last 4 quarters average of 44.3
ABT's price to book (P/B) is 66% higher than its 5-year quarterly average of 3.5 and 23% higher than its last 4 quarters average of 4.7
ABT's equity is down by 2.8% since the previous quarter and by 2.3% year-on-year
ABT's P/S is 49% above its 5-year quarterly average of 3.7 and 17% above its last 4 quarters average of 4.7
The revenue has grown by 4.5% YoY
Efficiency
How efficient is Abbott Laboratories business performance
Abbott Laboratories's return on assets has increased by 40% YoY
ABT's ROE is up by 34% YoY but it is down by 2.6% from the previous quarter
The ROIC has grown by 24% YoY
The ROS has grown by 18% YoY
Dividends
What is ABT's dividend history
DPS
$1.4
Dividend yield
1.4%
Payout ratio
69.3%
Recent dividends
Financial health
How did Abbott Laboratories financials performed over time
The total assets is 84% more than the total liabilities
ABT's quick ratio is down by 12% year-on-year and by 6% since the previous quarter
Abbott Laboratories's debt is 40% lower than its equity
ABT's equity is down by 2.8% since the previous quarter and by 2.3% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated
quarterly, unless otherwise specified.